65,437 trials
Attention Deficit Disorder With Hyperactivity
Primary: SKAMP (Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale) — -9.1; 5.6 score on a scale — p=<0.0001
Knee Osteoarthritis · Knee Rheumatism
Primary: Morphine Equivalence Consumption — 12.6; 18.85 MME
Alcohol Abuse
Primary: Change in Proportion of Binge Drinking Days — -0.13; -0.11 Binge Drinking Days
Leukemia · Lymphoma · Multiple Myeloma and Plasma Cell Neoplasm
Primary: Complete Remission Rate — 8; 6 Participants
Antidepressant Induced Sexual Dysfunction
Primary: Proportion of Participants in Remission Based on Arizona Sexual Experience Scale (ASEX) Score of 10 or Less After 12 Weeks of Treatment. — 2; 1 participants — p=0.55
Attention Deficit Disorder With Hyperactivity
Primary: Swanson, Nolan, and Pelham Questionnaire (SNAP-IV) — -1.09 score on a scale — p=0.01
Myocardial Infarction
Primary: Maximal Platelet Aggregation — 52; 64; 74 percent aggregation — p=0.011
Thermometry Device Comparisons
Primary: Temperature Agreement in Degrees Celsius. — NA; 0.5; 0.5; 0.4 Temperature in Celsius
Cervical Incompetence
Primary: Duration of Motor Block — 75; 99 minutes
Alcohol Abuse · Posttraumatic Stress Disorder
Primary: Percent Drinking Days Per Week — 18.1; 49.3 percentage of drinking days per week
Adenocarcinoma of the Prostate · Bone Metastases · Hormone-resistant Prostate Cancer
Primary: Progression-free Survival — 2.46; 3.65 Months — p=0.06
Dry Eye Syndromes · Sjogren's Syndrome
Primary: Schirmer Testing — 10.2; 0.8; 13.5 mm.
Alzheimer's Disease · Hypertension
Primary: Change in Cerebrospinal Fluid (CSF) Amyloid Beta-42 (Aβ42) Levels Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo — -22.5; -31.71 pg/ml…
Lymphangioleiomyomatosis · Tuberous Sclerosis Complex
Primary: Safety of Simvastatin in the Treatment of LAM-S and LAM-TS Patients — 0 participants
Postoperative Nausea and Vomiting
Primary: Post-operative Nausea Scores — NA; NA; NA; NA participants